Jefferies Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsInitiationPrice Target
Jefferies analyst Akash Tewari initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $35.
Jefferies analyst Akash Tewari initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $35.